Mayne Pharma Group Limited
ASX: MYX
NEXTSTELLIS-fueled growth narrows losses for Mayne Pharma.
(Source: TradingView) 3-Month Performance Profile of MYX on a DTF compared to S&P/ASX 200 (XJO).
Mayne Pharma’s FY25 net loss stood at $93.84 million, narrowing by 46.14% year-over-year, supported by strong performance in the Women’s Health segment, where revenue surged 23% to $115.5 million. The
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
